What are the risks of prescribing propranolol to a patient with anorexia nervosa, major depressive disorder, and anxiety?

Propranolol Should Be Used with Extreme Caution in Patients with Anorexia Nervosa, MDD, and Anxiety

Propranolol carries significant risks in this population, particularly worsening depression and exacerbating anorexia-related symptoms, and should generally be avoided unless there is a compelling cardiovascular indication that cannot be managed with alternative agents.

Key Risks in This Population

Depression Risk

Beta-blockers, particularly propranolol, are associated with depression as a documented adverse effect. The FDA label explicitly lists "mental depression manifested by insomnia, lassitude, weakness, fatigue" as an adverse reaction 1. Multiple cardiovascular guidelines acknowledge that long-term beta-blocker therapy may confer clinical risks including depression 2.

The evidence suggests propranolol can cause organic mood disorder, depressed type, with side effects including fatigue, diminished energy, decreased libido, anorexia, and poor concentration 3. In a patient already diagnosed with MDD, propranolol could significantly worsen depressive symptoms. Case reports document severe depression with marked apathy, social withdrawal, and anorexia developing within months of propranolol initiation 4.

Critical consideration: The lipophilic nature of propranolol allows high brain concentrations, increasing central nervous system effects including depression 4. Patients with a positive personal or family history of depression show significantly higher depression scores on propranolol 5.

Anorexia-Specific Concerns

The combination is particularly problematic because:

• Propranolol's adverse effects include anorexia 3, which directly worsens the primary eating disorder
• Underweight patients with anorexia nervosa have altered pharmacokinetics due to malnutrition and cachexia 6
• The medication can cause bradycardia and hypotension 1, which are already common complications in severely malnourished anorexia patients
• Propranolol may mask compensatory tachycardia that occurs with refeeding or dehydration

Anxiety Treatment Paradox

Despite propranolol being commonly prescribed for anxiety, recent systematic review evidence shows no beneficial effect of beta-blockers compared with placebo or benzodiazepines in patients with social phobia or panic disorder 7. This is particularly relevant since the 2025 meta-analysis found insufficient evidence to support beta-blocker use for anxiety disorders, yet prescriptions have increased substantially 7.

Guidelines do note that beta-blockers are commonly prescribed for panic disorder symptom relief 8, but this appears to be based more on clinical practice than robust evidence.

Specific Clinical Pitfalls

Cardiovascular Complications

In underweight anorexia patients, propranolol poses additional risks:

• Bradycardia risk is amplified - anorexia patients often already have baseline bradycardia 1
• Hypotension - both the disease and medication cause this 1
• Impaired hepatic function common in malnutrition affects propranolol metabolism, as the FDA label warns to use with caution in hepatic impairment 1

Drug Interactions

The FDA label warns about multiple drug interactions 1:

• If the patient is on SSRIs for depression (common in this population), there may be CYP2D6 interactions
• Alcohol increases propranolol plasma levels 1

Alternative Approach

If beta-blockade is absolutely necessary for a cardiovascular indication:

• Consider atenolol instead - it is weakly lipophilic with lower brain penetration and has been successfully substituted in patients who developed depression on propranolol 4
• Case reports show complete remission of propranolol-induced depression when switched to atenolol 4

For anxiety management:

• Given the lack of evidence for beta-blocker efficacy in anxiety disorders 7, prioritize SSRIs (sertraline or escitalopram have better safety profiles) 2 or cognitive behavioral therapy
• Note that fluoxetine may be beneficial for depression in weight-restored anorexia patients 9

For depression in underweight patients:

• Evidence for antidepressant efficacy in underweight anorexia patients is insufficient 10
• Weight restoration should be prioritized, as depression often improves with nutritional rehabilitation
• If antidepressants are used, avoid tricyclics entirely (cause hypotension and arrhythmias) 2

Bottom Line

The combination of propranolol with anorexia nervosa, MDD, and anxiety creates a perfect storm of overlapping adverse effects - worsening depression, exacerbating anorexia, causing bradycardia and hypotension in an already compromised patient. Unless there is a life-threatening cardiovascular indication (e.g., thyroid storm, severe tachyarrhythmia), avoid propranolol in this population. If beta-blockade is unavoidable, use a cardioselective agent like atenolol with close monitoring for worsening psychiatric symptoms and cardiovascular instability.